Braveheart Bio, Inc. (NASDAQ:BRVE) Short Interest Update

Braveheart Bio, Inc. (NASDAQ:BRVE) saw a large growth in short interest in August. As of August 14th, there was short interest totaling 847,773 shares, a growth of ? from the July 30th total of 0 shares. Based on an average daily trading volume, of 650,680 shares, the short-interest ratio is presently 1.3 days. Approximately 1.2% of the shares of the stock are sold short.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Braveheart Bio in a research note on Monday. They issued an “overweight” rating and a $40.00 price objective on the stock. TD Cowen started coverage on shares of Braveheart Bio in a research note on Monday. They set a “buy” rating for the company. The Goldman Sachs Group began coverage on shares of Braveheart Bio in a report on Monday. They set a “buy” rating and a $48.00 target price for the company. Stifel Nicolaus began coverage on shares of Braveheart Bio in a research report on Monday. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Jefferies Financial Group assumed coverage on Braveheart Bio in a report on Monday. They issued a “buy” rating and a $48.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $45.25.

Insiders Place Their Bets

In other news, Director Erez Chimovits acquired 1,940,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the completion of the acquisition, the director directly owned 11,901,826 shares in the company, valued at $214,232,868. This represents a 19.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director David Charles Lubner bought 55,555 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average cost of $18.00 per share, with a total value of $999,990.00. Following the purchase, the director directly owned 55,555 shares of the company’s stock, valued at approximately $999,990. This represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 8,751,942 shares of company stock valued at $157,534,956.

Braveheart Bio Price Performance

NASDAQ:BRVE traded down $1.39 during trading hours on Monday, hitting $26.05. 400,440 shares of the stock traded hands, compared to its average volume of 338,682. Braveheart Bio has a fifty-two week low of $24.61 and a fifty-two week high of $32.00.

Braveheart Bio Company Profile

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.